Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-

Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone

First Posted Date
2010-05-07
Last Posted Date
2015-06-24
Lead Sponsor
Abarbanel Mental Health Center
Target Recruit Count
40
Registration Number
NCT01119638
Locations
🇮🇱

Abarbanel MHC, Bat-Yam, Israel

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-10-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
237
Registration Number
NCT01111552
Locations
🇷🇴

Study Site 1, Bucuresti, Romania

🇷🇴

Study Site 2, Bucuresti, Romania

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-12-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
137
Registration Number
NCT01111565
Locations
🇿🇦

Study Site 1, Cape Town, South Africa

🇿🇦

Study Site 2, Cape Town, South Africa

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-10-20
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
211
Registration Number
NCT01111539
Locations
🇮🇳

Study Site 1, Ahmedabad, Gujarat, India

🇮🇳

Study Site 2, Ahmedabad, Gujarat, India

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2010-04-14
Last Posted Date
2019-06-14
Lead Sponsor
University of Chicago
Target Recruit Count
70
Registration Number
NCT01103180
Locations
🇺🇸

The University of Chicago Hospitals, Chicago, Illinois, United States

Neural Responses and Dysphoria: Modulation by a Pharmacological Probe

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-04-12
Last Posted Date
2011-06-07
Lead Sponsor
University of Oxford
Target Recruit Count
160
Registration Number
NCT01101685
Locations
🇬🇧

Department of Psychiatry, Oxford, United Kingdom

TMC435-TiDP16-C112 - Interaction Trial With Antidepressants

First Posted Date
2010-03-22
Last Posted Date
2013-04-09
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
20
Registration Number
NCT01090700

Biomarkers for Outcomes In Late-life Depression (BOLD)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-03-08
Last Posted Date
2013-04-16
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
80
Registration Number
NCT01082237
Locations
🇺🇸

UCLA Semel Institute, Los Angeles, California, United States

Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype

First Posted Date
2010-03-02
Last Posted Date
2010-03-10
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
75
Registration Number
NCT01078870
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath